A Pilot Trial of Clazakizumab in Late ABMR

Antibody-mediated Rejection Clinical Trial

Official title:

Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03444103
• Other study ID #: EK1428/2017
• Secondary ID: 2017-001604-30
• Status: Completed
• Phase: Phase 2
• Start date: January 16, 2018
• Est. completion date: June 30, 2020

Study information

• Verified date: September 2020
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This bi-center study (Medical University of Vienna & Charité Berlin) is an investigator-driven pilot trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy (preliminary assessment) of humanized anti-IL-6 monoclonal antibody clazakizumab in kidney transplant recipients with late antibody-mediated rejection (ABMR). The study is designed as a phase 2 trial and has two subsequent sub-parts, a randomized placebo-controlled trial (part A) of 12 weeks, where recipients are allocated to receive either anti-IL-6 antibody clazakizumab (n=10) or placebo (n=10), followed by an open-label prospective study, where all 20 study patients will receive clazakizumab for a period of 40 weeks. Study protocol biopsies will be performed at the end of part A and part B.

Description:

Part A:

Patients positive for anti-HLA donor-specific antibodies (DSA) and with biopsy-proven late ABMR (Acute/active or chronic/active phenotype according to the Banff 2015 classification) will be identified and recruited at the kidney transplantation outpatient services of the two center sites. Participants will be randomized to receive either clazakizumab or placebo subcutaneously (1:1 randomization stratified for ABMR type) for a period of 12 weeks (administration of clazakizumab/placebo at day 0, and after 4 and 8 weeks). After 12 weeks, patients will be subjected to a first follow-up biopsy. Primary goals of this part of the trial are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a short course of treatment. Moreover, part A will allow for a first preliminary assessment of the impact of clazakizumab on ABMR-associated inflammation detected in peripheral blood and in the rejecting organ allograft, on the pharmacokinetics of pantoprazole as a probe drug to investigate influence of IL-6 blockade on cytochrome P450 (CYP) dependent drug metabolism (potential effects on the half-life of CYP-metabolized drugs such as pantoprazole, and on the short-term course of DSA mean fluorescence intensity (MFI) and kidney allograft function (eGFR, urinary protein excretion). The randomization sequence will be unblinded for a first data analysis after the last patient has completed the 12-week follow-up period.

Part B:

After completion of part A after 12 weeks, all study patients will enter part B, an open-label part of the study. All 20 subjects will receive subcutaneous clazakizumab in 4-weekly intervals until the end-of-study (EOS) visit after 52 weeks and will then be subjected to a second protocol biopsy. Major goals of part B are to evaluate the safety and tolerability of a prolonged period of treatment with clazakizumab and the long-term impact of this antibody on the evolution of ABMR, rejection-associated biomarkers and kidney allograft function and survival over a period of 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 30, 2020
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Voluntary written informed consent

• Age >18 years

• Functioning living or deceased donor allograft after =365 days post-transplantation

• eGFR >30 ml/min/1.73 m2

• Detection of HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).

• Acute/active or chronic/active ABMR (±C4d in PTC) according to Banff 2013/2015

• Molecular ABMR score (ABMRpm) =0.2

Exclusion Criteria:

• Patients actively participating in another clinical trial

• Age =18 years

• Female subject is pregnant or lactating

• Index biopsy results:

• T-cell-mediated rejection classified Banff grade =I

• De novo or recurrent severe thrombotic microangiopathy

• Polyoma virus nephropathy

• De novo or recurrent glomerulonephritis

• Acute rejection treatment <3 month before screening

• Acute deterioration of graft function (eGFR decline within 1-3 months >25%)

• Nephrotic range proteinuria >3500 mg/g protein/creatinine ratio

• Active viral, bacterial or fungal infection precluding intensified immunosuppression

• Active malignant disease precluding intensified immunosuppressive therapy

• Abnormal liver function tests (ALT, AST, bilirubin > 1.5 x upper limit of normal)

• Other significant liver disease

• Latent or active tuberculosis (positive QuantiFERON-TB-Gold test, Chest X-ray)

• Administration of a live vaccine within 6 weeks of screening

• Neutropenia (<1 G/L) or thrombocytopenia (<100 G/L)

• History of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease

• Allergy against proton pump inhibitors

• History of alcohol or illicit substance abuse

• Serious medical or psychiatric illness likely to interfere with participation in the study

Related Conditions & MeSH terms

• Antibody-mediated Rejection

Intervention

Drug:
• Clazakizumab / Clazakizumab
Humanized monoclonal anti-IL-6 antibody
• Placebo / Clazakizumab
0.9% Saline

Locations

Country	Name	City	State
Austria	Medical University of Vienna	Vienna
Germany	Charité University	Berlin

Sponsors (4)

Lead Sponsor	Collaborator
Medical University of Vienna	Charite University, Berlin, Germany, CSL Behring, University of Alberta

Countries where clinical trial is conducted

Austria,  Germany, 

References & Publications (3)

Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant. 2017 Sep;17(9):2381-2389. doi: 10.1111/ajt.14228. Epub 2017 Mar 10. — View Citation

Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14. — View Citation

Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events and severe adverse events (AE's, SAE's)	Serious and Non-Serious adverse events probably or possibly attributable to clazakizumab	12 months
Secondary	Anti-clazakizumab antibodies in serum	- Concentration of anti-clazakizumab antibodies in serum (ng/mL)	At 0, 12 and 52 weeks
Secondary	Clazakizumab serum concentration	- Total clazakizumab serum concentration (ng/mL)	At 0, 12 and 52 weeks
Secondary	Pantoprazole serum concentration	- Effect of clazakizumab on pantoprazole serum concentration (nanogram per mL)	At 0, 12 and 52 weeks
Secondary	Protocol biopsy results - microcirculation inflammation	- Microcirculation inflammation (g+ptc score), scale 0-3, higher = worse prognosis	At week 11 and at week 52
Secondary	Protocol biopsy results - chronic damage	- Transplant glomerulopathy (cg) and interstitial fibrosis/tubular atrophy (IFTA) scores, scale 0-3, higher = worse prognosis	At week 11 and at week 52
Secondary	Protocol biopsy results - molecular signs of ABMR	- Molecular ABMR score (molecular microscope, MMDx), scale 0-1 in 0.1 steps, higher = worse prognosis	At week 11 and at week 52
Secondary	Protocol biopsy results - ABMR phenotype	- Archetype analysis of gene expression profiles (molecular microscope, MMDx), ABMR archetype score, scale 0-1 in 0.1 steps, higher = worse prognosis	At week 11 and at week 52
Secondary	Anti-HLA antibody levels - antibody strength	- Maximum and sum of mean fluorescence intensity (MFI) of DSA (Luminex) - higher is worse	At 0, 12 and 52 weeks
Secondary	Anti-HLA antibody levels - number of DSA	- Number of DSA (Luminex) - more is worse	At 0, 12 and 52 weeks
Secondary	Anti-HLA antibody levels - broadness of antibody reactivity	- Broadness of sensitization (virtual PRA, Luminex), scale: %, higher = worse	At 0, 12 and 52 weeks
Secondary	Allograft function - eGFR	- Estimated GFR (CKD-EPI, mL/min/1.73m2)	At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
Secondary	Allograft function - protein excretion in spot urine	- Urinary protein excretion in spot urine (protein/creatinine ratio in mg/g)	At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
Secondary	Total IgG concentration	- Nephelometry, mg/dL	At 0, 12 and 52 weeks
Secondary	Total IgM concentration	- Nephelometry, mg/dL	At 0, 12 and 52 weeks
Secondary	Total IgA concentration	- Nephelometry, mg/dL	At 0, 12 and 52 weeks
Secondary	IgG subclass 1 (IgG1)	- ELISA, mg/dL	At 0, 12 and 52 weeks
Secondary	IgG subclass 2 (IgG2)	- ELISA, mg/dL	At 0, 12 and 52 weeks
Secondary	IgG subclass 3 (IgG3)	- ELISA, mg/dL	At 0, 12 and 52 weeks
Secondary	IgG subclass 4 (IgG4)	- ELISA, mg/dL	At 0, 12 and 52 weeks
Secondary	Effect on leukocyte subsets in peripheral blood	- Fluorescence intensity (0 to no upper limit)	At 0, 12 and 52 weeks
Secondary	Cytokine patterns and endothelial activation/injury markers in serum	- Luminex bead panels, mean fluorescence intensities (MFI)	At 0, 12 and 52 weeks
Secondary	Effect on IL-6 gene expression in peripheral blood cells	rtPCR	At 0, 12 and 52 weeks
Secondary	Effect on IL-6R gene expression in peripheral blood cells	rtPCR	At 0, 12 and 52 weeks
Secondary	Patient survival	Death: number of events, time to event	12 months
Secondary	Graft survival	Graft loss: number of events, time to event	12 months
Secondary	Occurrence of biopsy-proven acute rejection necessitating rejection treatment	Number of anti-rejection treatments with a substance other than the study drug	At week 52

External Links

•   Vienna Transplant and Complement Laboratory (VIETAC) website
•   Vitaeris website